Results 151 to 160 of about 12,566 (192)
Some of the next articles are maybe not open access.
Drugs, 1998
Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in obese, but otherwise healthy, patients during < or = 2 years' orlistat ...
W, McNeely, P, Benfield
+5 more sources
Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in obese, but otherwise healthy, patients during < or = 2 years' orlistat ...
W, McNeely, P, Benfield
+5 more sources
Intensive and Critical Care Nursing, 1999
The introduction of orlistat (Roche, UK) at the end of last year received considerable media coverage and was heralded in some quarters as the 'quick fix' for those wishing to lose weight without the pain of dieting. This description is far from accurate but treatment with orlistat may have a role in patients for whom obesity is a serious and even life-
Crenier, Laurent, Sternon, J.
openaire +5 more sources
The introduction of orlistat (Roche, UK) at the end of last year received considerable media coverage and was heralded in some quarters as the 'quick fix' for those wishing to lose weight without the pain of dieting. This description is far from accurate but treatment with orlistat may have a role in patients for whom obesity is a serious and even life-
Crenier, Laurent, Sternon, J.
openaire +5 more sources
Molecular Pharmaceutics, 2019 Orlistat, an FDA-approved antiobesity drug, has recently been shown to have anticancer effects. However, orlistat is extremely hydrophobic with low absorption.
Jun F Liang, Tianchi Liu, Tzu-Lan Chang
exaly +2 more sources
Hospital Pharmacy, 1999
Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +1 more source